Microbial Metabolites in Multiple Sclerosis: Implications for Pathogenesis and Treatment

Overview

Journal Front Neurosci

Date 2022 May 16

PMID 35573295

Authors

Eduardo Duarte-Silva

Sven G Meuth

Christina Alves Peixoto

Affiliations

Soon will be listed here.

Abstract

Metabolites produced by the gut microbiota have been shown to play an important role in numerous inflammatory, neuropsychiatric, and neurodegenerative diseases. Specifically, microbial metabolites have been implicated in the modulation of innate and adaptive immunity, especially in the generation of regulatory T cells (Tregs), which are key regulators of multiple sclerosis (MS) pathogenesis. Furthermore, they affect processes relevant to MS pathophysiology, such as inflammation and demyelination, which makes them attractive molecules to be explored as therapeutics in MS. In this review, we discuss the importance of these metabolites as factors contributing to disease pathogenesis and as therapeutic targets in MS. Establishing an improved understanding of these gut-microbiota derived metabolites may provide new avenues for the treatment of MS.

Citing Articles

Gut microbiota in health and disease: advances and future prospects.

Zhang Y, Wang H, Sang Y, Liu M, Wang Q, Yang H MedComm (2020). 2024; 5(12):e70012.

PMID: 39568773 PMC: 11577303. DOI: 10.1002/mco2.70012.

Gut Bacteria Provide Genetic and Molecular Reporter Systems to Identify Specific Diseases.

Dicks L Int J Mol Sci. 2024; 25(8).

PMID: 38674014 PMC: 11050607. DOI: 10.3390/ijms25084431.

The Gut-Brain Axis as a Therapeutic Target in Multiple Sclerosis.

Buga A, Padureanu V, Riza A, Oancea C, Albu C, Nica A Cells. 2023; 12(14).

PMID: 37508537 PMC: 10378521. DOI: 10.3390/cells12141872.

Multiple Sclerosis-Related Dietary and Nutritional Issues: An Updated Scoping Review with a Focus on Pediatrics.

Mandato C, Colucci A, Lanzillo R, Staiano A, Scarpato E, Schiavo L Children (Basel). 2023; 10(6).

PMID: 37371254 PMC: 10297186. DOI: 10.3390/children10061022.

The role of iron metabolism in the pathogenesis and treatment of multiple sclerosis.

Duarte-Silva E, Meuth S, Peixoto C Front Immunol. 2023; 14:1137635.

PMID: 37006264 PMC: 10064139. DOI: 10.3389/fimmu.2023.1137635.

References

Duarte-Silva E, Macedo D, Maes M, Peixoto C . Novel insights into the mechanisms underlying depression-associated experimental autoimmune encephalomyelitis. Prog Neuropsychopharmacol Biol Psychiatry. 2019; 93:1-10. DOI: 10.1016/j.pnpbp.2019.03.001. View

Jangi S, Gandhi R, Cox L, Li N, von Glehn F, Yan R . Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016; 7:12015. PMC: 4931233. DOI: 10.1038/ncomms12015. View

Takewaki D, Suda W, Sato W, Takayasu L, Kumar N, Kimura K . Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. Proc Natl Acad Sci U S A. 2020; 117(36):22402-22412. PMC: 7486801. DOI: 10.1073/pnas.2011703117. View

van der Hee B, Wells J . Microbial Regulation of Host Physiology by Short-chain Fatty Acids. Trends Microbiol. 2021; 29(8):700-712. DOI: 10.1016/j.tim.2021.02.001. View

Choi Y, Park H . Anti-inflammatory effects of spermidine in lipopolysaccharide-stimulated BV2 microglial cells. J Biomed Sci. 2012; 19:31. PMC: 3320531. DOI: 10.1186/1423-0127-19-31. View

Reynders T, Devolder L, Valles-Colomer M, Van Remoortel A, Joossens M, De Keyser J . Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes. Ann Clin Transl Neurol. 2020; 7(4):406-419. PMC: 7187717. DOI: 10.1002/acn3.51004. View

Wagner A, Wang C, Fessler J, DeTomaso D, Avila-Pacheco J, Kaminski J . Metabolic modeling of single Th17 cells reveals regulators of autoimmunity. Cell. 2021; 184(16):4168-4185.e21. PMC: 8621950. DOI: 10.1016/j.cell.2021.05.045. View

Escobar J, Cortese M, Edan G, Freedman M, Hartung H, Montalban X . Body mass index as a predictor of MS activity and progression among participants in BENEFIT. Mult Scler. 2022; 28(8):1277-1285. PMC: 9187580. DOI: 10.1177/13524585211061861. View

Saresella M, Marventano I, Barone M, La Rosa F, Piancone F, Mendozzi L . Alterations in Circulating Fatty Acid Are Associated With Gut Microbiota Dysbiosis and Inflammation in Multiple Sclerosis. Front Immunol. 2020; 11:1390. PMC: 7358580. DOI: 10.3389/fimmu.2020.01390. View

10.

Beurel E, Lowell J, Jope R . Distinct characteristics of hippocampal pathogenic T17 cells in a mouse model of depression. Brain Behav Immun. 2018; 73:180-191. PMC: 6287768. DOI: 10.1016/j.bbi.2018.04.012. View

11.

Camara-Lemarroy C, Silva C, Greenfield J, Liu W, Metz L, Yong V . Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity. Mult Scler. 2019; 26(11):1340-1350. DOI: 10.1177/1352458519863133. View

12.

Puleston D, Baixauli F, Sanin D, Edwards-Hicks J, Villa M, Kabat A . Polyamine metabolism is a central determinant of helper T cell lineage fidelity. Cell. 2021; 184(16):4186-4202.e20. PMC: 8358979. DOI: 10.1016/j.cell.2021.06.007. View

13.

Berer K, Gerdes L, Cekanaviciute E, Jia X, Xiao L, Xia Z . Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017; 114(40):10719-10724. PMC: 5635914. DOI: 10.1073/pnas.1711233114. View

14.

Kim C . Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. Cell Mol Immunol. 2021; 18(5):1161-1171. PMC: 8093302. DOI: 10.1038/s41423-020-00625-0. View

15.

Yang Q, Zheng C, Cao J, Cao G, Shou P, Lin L . Spermidine alleviates experimental autoimmune encephalomyelitis through inducing inhibitory macrophages. Cell Death Differ. 2016; 23(11):1850-1861. PMC: 5071574. DOI: 10.1038/cdd.2016.71. View

16.

DaSilva N, Nahar P, Ma H, Eid A, Wei Z, Meschwitz S . Pomegranate ellagitannin-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation in vitro. Nutr Neurosci. 2017; 22(3):185-195. DOI: 10.1080/1028415X.2017.1360558. View

17.

Duscha A, Gisevius B, Hirschberg S, Yissachar N, Stangl G, Dawin E . Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism. Cell. 2020; 180(6):1067-1080.e16. DOI: 10.1016/j.cell.2020.02.035. View

18.

Buscarinu M, Cerasoli B, Annibali V, Policano C, Lionetto L, Capi M . Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study. Mult Scler. 2016; 23(3):442-446. DOI: 10.1177/1352458516652498. View

19.

Baecher-Allan C, Kaskow B, Weiner H . Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018; 97(4):742-768. DOI: 10.1016/j.neuron.2018.01.021. View

20.

Pellizoni F, Leite A, Rodrigues N, Ubaiz M, Gonzaga M, Takaoka N . Detection of Dysbiosis and Increased Intestinal Permeability in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis. Int J Environ Res Public Health. 2021; 18(9). PMC: 8123689. DOI: 10.3390/ijerph18094621. View